Navigation Links
Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

Albany, New York (PRWEB) August 22, 2014

Ophthalmic drug delivery technologies or mechanisms represent one of the interesting and challenging endeavors as the anatomy, physiology and biochemistry of the eye renders highly impervious properties to the foreign substances. Ocular drug delivery technologies provide several advantages such as possibility of self medication and minimal use of needles; also it enables high penetration of low molecular weight drugs and provides specific targeting within the ocular globe. On the other hand limited permeability of cornea results in low absorption of the drugs and also it renders brisk elimination of drug through the eye due to blinking and continuous tear flow and can cause unwanted systemic side effects as major portion of the dose is drained into lacrimal ducts. These factors collectively impact the growth and acceptance of several ocular drug delivery technologies. The various approaches adopted to ensure development of effective drug delivery technologies are controlled and sustained release of drugs and improvement in bioavailability. Lacrisert, Retisert, Vitrasert, Durasite and Microneedle are some of the instances of patented technologies employed in ocular drug delivery systems.

Eye drops, systemic means, topical means and intraocular injections represent the conventional means of ocular drug delivery mechanisms. These mechanisms have several disadvantages such as increased patient discomfort, less efficient, low absorption and other side effects. Hence, this leads to the development of alternative and effective systems for delivery of ophthalmic medications. Intense research is carried out to ensure sustained and controlled release of the active agents with negligible side effects. It is observed that several drug delivery technologies are in developmental phases. For instance, intravitreal injections constitute an effective and direct approach to deliver medications to the posterior segment. However, these are associated with severe side effects such as vitreous hemorrhage, endophthalmitis, retinal detachment and cataract.

Early buyers will receive 10% customization on this report:

Hence, there is a need of sustained release devices that provide alternative routes for delivering drugs to the eye such as erodible and biodegradable or non-biodegradable inserts. In addition, use of biodegradable polymer nanoparticles as carriers for targeted drug delivery is one of the promising technologies and is still in developmental phases. In case of glaucoma medications, researchers are focusing on use of drug eluting ocular conformers with antifibrotic agents placed in contact lenses, punctual plugs and glaucoma shunts to deliver glaucoma drugs to eyes.

The market for ocular drug delivery technologies can be segmented on the basis of the type of the drug delivery systems and geography. The geography includes the analysis of the ocular drug delivery technologies in four major geographies namely North America, Asia-Pacific, Europe and Rest of the World. Ozurdex (by Allergan) refers to a biodegradable implant that enables prolonged delivery of steroids and is recently approved by the U.S. FDA to treat macular edema. Retisert (by Bausch + Lomb) is non-biodegradable and is approved for noninfectious posterior uvetitis and requires surgical implantation to sclera. Prodrugs (pharmacological materials administered in an inactive form). These substances are an effective alternative to the injectable devices. For instance, Cortiject (by Novagali Pharma) is an emulsion without solvent and preservatives and encloses a tissue activated corticosteroid prodrug. This is in the phase I and currently designed for patients with diabetic retinopathy. Development of hydrogel contact lenses, novel punctual plugs and intraocular pump implants constitute the other developments in ocular drug delivery technologies. In addition, the events such as research and development projects, product approvals, strategic partnerships and alliances by the key players also strongly impact the market growth.

Some of the major factors that influence the market growth are increasing ocular disorders across the globe and increased need and demand for continuous medications. These in turn augment the need and demand for effective drug delivering technologies. In addition, consistent technological advances such as promising field of nanomedicine. Nanocarriers (nanoparticles, dendrimers, and liposomes) are currently under experimental phases in order to use them as a means of effective ocular drug delivery. On the other hand, high cost involved in the research and lack of accessibility of these technologies are some of the factors that might affect adoption and use of these technologies. Hoya Corporation, Bausch & Lomb, Inc., Abbott Medical Optics and CooperVision, Inc. are some of the companies operating in this market.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of

  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years

Request for customization of this report:

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report

  • This report provides pin-point analysis for changing competitive dynamics
  • It provides a forward looking perspective on different factors driving or restraining market growth
  • It provides a six-year forecast assessed on the basis of how the market is predicted to grow
  • It helps in understanding the key product segments and their future
  • It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
  • It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
  • It provides distinctive graphics and exemplified SWOT analysis of major market segments

Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA/Canada Toll Free: 866-552-3453
Email: sales(at)transparencymarketresearch(dot)com

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Intraocular Lens (IOL) Market Worth $3.8 Billion By 2018 Say New Research Report at
2. Pine Grove Nursing Center Uses AccuNurse Interactive Care to Improve Care and Service Delivery
3. ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets
4. Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award
5. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
6. Successful human tests for first wirelessly controlled drug-delivery chip
7. First successful human results achieved: Implantable wireless microchip drug delivery device
8. Floridas Leading Fertility Center Announces Successful Baby Delivery via Egg Freezing
9. New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation
10. McLean Report on nanotechnology that may enhance medication delivery and improve MRI performance
11. BioRestorative Therapies Announces Next Generation of Stem Cell Disc Delivery Device
Post Your Comments:
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf ... the 2016 USGA Green Section Award. Presented annually since 1961, the USGA Green Section ... her work with turfgrass. , Clarke, of Iselin, N.J., is an extension ...
Breaking Biology Technology:
(Date:11/18/2015)... PHILADELPHIA , Nov. 18, 2015  As new ... in children, doctors and other healthcare providers face challenges ... counsel families and patients. In addition, as more children ... into a patient,s adulthood and old age. ... The Children,s Hospital of Philadelphia (CHOP) . ...
(Date:11/17/2015)... Calif. , Nov. 17, 2015  Vigilant Solutions ... has joined its Board of Directors. ... Board after recently retiring from the partnership at TPG ... 107 companies with over $140 Billion in revenue.  He ... improvement across all the TPG companies, from 1997 to ...
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
Breaking Biology News(10 mins):